Current recommendations for the management of bladder cancer. Drug therapy (Q41388302)

30 September 2017

1 reference

title

Current recommendations for the management of bladder cancer. Drug therapy (English)

1 reference

30 September 2017

Witjes JA

1

1 reference

30 September 2017

1 March 1997

1 reference

30 September 2017

1 reference

30 September 2017

53

1 reference

30 September 2017

3

1 reference

30 September 2017

404-414

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753030-00005

30 September 2017

0 references

cites work

Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer

1 reference

12 December 2020

Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro

1 reference

12 December 2020

Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup

1 reference

12 December 2020

Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

1 reference

12 December 2020

Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone

1 reference

12 December 2020

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer

1 reference

12 December 2020

Complications of intravesical chemotherapy

1 reference

12 December 2020

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

12 December 2020

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

12 December 2020

Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study

1 reference

12 December 2020

Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview

1 reference

12 December 2020

Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group

1 reference

12 December 2020

Intravesical interferon treatment of superficial bladder cancer

1 reference

12 December 2020

Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases

1 reference

12 December 2020

Surveillance of stage O, grade I bladder cancer by cytology alone--is it acceptable?

1 reference

12 December 2020

Phase 1 trial of oral bropirimine in superficial bladder cancer

1 reference

12 December 2020

Intravesical chemotherapy. Treatment selection, techniques, and results

1 reference

12 December 2020

Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study

1 reference

12 December 2020

A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group

1 reference

12 December 2020

Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer

1 reference

12 December 2020

The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer

1 reference

12 December 2020

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

1 reference

12 December 2020

Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO.

1 reference

12 December 2020

Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer

1 reference

12 December 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer

1 reference

12 December 2020

The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group

1 reference

12 December 2020

Long-term results of intravesical therapy for superficial bladder cancer

1 reference

12 December 2020

[Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses]

1 reference

12 December 2020

Prognostic factors in superficial bladder cancer. A review

1 reference

12 December 2020

A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

1 reference

12 December 2020

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

1 reference

12 December 2020

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

1 reference

12 December 2020

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

12 December 2020

Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group

1 reference

12 December 2020

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

12 December 2020

Improving the efficacy of BCG immunotherapy by dose reduction

1 reference

12 December 2020

Selecting initial therapy for bladder cancer

1 reference

12 December 2020

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

12 December 2020

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions)

1 reference

12 December 2020

Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma

1 reference

12 December 2020

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

12 December 2020

Promotive effects of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice

1 reference

12 December 2020

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

1 reference

12 December 2020

The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin

1 reference

12 December 2020

Decreasing bladder cancer mortality in The Netherlands

1 reference

12 December 2020

Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors

1 reference

12 December 2020

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin

1 reference

12 December 2020

The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes)

1 reference

12 December 2020

The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder

1 reference

12 December 2020

The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent

1 reference

12 December 2020

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder

1 reference

12 December 2020

10.2165/00003495-199753030-00005

Identifiers

DOI

1 reference

PubMed ID

9074842

Dimensions Publication ID

30 September 2017

0 references

1 reference

PubMed ID

9074842